CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022

Chimeric antigen receptor (CAR)-NK cell therapy has the advantages of a low incidence of side effects and a low cost. However, the clinical outcomes are not satisfactory due to limited antitumor effects and a limited proliferative capacity. Recently, progress in CAR-NK cell therapy has been made in...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Ruihao, Wen, Qin, Zhang, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082521/
https://www.ncbi.nlm.nih.gov/pubmed/37029381
http://dx.doi.org/10.1186/s13045-023-01435-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082521/
https://www.ncbi.nlm.nih.gov/pubmed/37029381
http://dx.doi.org/10.1186/s13045-023-01435-3

Ejemplares similares